The Association for Accessible Medicines and its Biosimilars Council have released an analysis undertaken by the IQVIA Institute for Human Data Science on behalf of AAM assessing the impact of patent ...

The Inflation Reduction Act (IRA) has reshaped how Medicare covers and reimburses prescription drugs. For the first time, the ...

Both Alvotech ALVO and Teva Pharmaceuticals TEVA operate in the biosimilar space, but their business models differ significantly. ALVO has built its revenue model around partnerships, relying on ...

Add Yahoo as a preferred source to see more of our stories on Google. Draft guidance from the FDA would allow companies to scale back on the studies and trials needed to prove that a biosimilar ...

Each year, the FDA approves a wide range of medications that help shape the future of medicine in the U.S. These include novel drugs that offer new treatment options, as well as first generics and ...

Sandoz has not minced words about the massive, yet largely untapped opportunity biosimilar makers are presented with as dozens of branded medicines inch toward the patent cliff in the next decade.& | ...

In 2024, the use of generic and biosimilar medicines saved $467 billion for the United States health-care system and the patients who use it, according to a recent report by the Association for ...

The US Food and Drug Administration is easing some requirements for drugmakers developing copycat versions of costly biologic ...

Detailed price information for Sandoz Group Ag ADR (SDZNY) from The Globe and Mail including charting and trades.

Sandoz announced the creation of a new biosimilar development, manufacturing and supply unit that will be headed by industry veteran Armin Metzger, who will join Sandoz on April 1.

The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...